Dear Colleagues,

α-Synucleinopathies are a group of neurodegenerative disorders characterized by the abnormal accumulation of α-synuclein protein in the brain. These disorders include Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The pathogenesis of α-synucleinopathies is not completely understood, and societal issues are associated with both the diagnosis and treatment of these disorders. One of the primary factors in α-synucleinopathies is the cause of the abnormal accumulation of α-synuclein protein. Both genetic and environmental factors are involved; however, the exact mechanisms are still not well understood. Additionally, it is not yet clear whether the accumulation of α-synuclein is the cause of the neurodegeneration in these disorders or if it is a secondary effect. Another uncertainty is the lack of reliable biomarkers for α-synucleinopathies. Currently, the diagnosis of these disorders relies on clinical symptoms, which can be difficult to distinguish from other neurodegenerative diseases. Developing accurate biomarkers could lead to earlier diagnosis and better treatment options. Therefore, it is necessary to explore pathogenic mechanisms to find novel therapeutic targets and unique biomarkers.

This special issue aims to advance understanding of the pathogenic mechanism of α-synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The abnormal accumulation of α-synuclein protein is a hallmark of these disorders, but the exact mechanisms that lead to this accumulation and subsequent neurodegeneration are not yet fully understood. By studying the pathogenic mechanisms of these disorders, we hope to identify novel therapeutic targets for the development of effective treatments and investigate unique biomarkers to reveal their physiological significance. We welcome a wide range of topics, from basic science to clinical research on α-synucleinopathies.

Dr. Ichiro Kawahata and Dr. Kohji Fukunaga
Guest Editors